Neuropathology of progressive supranuclear palsy after treatment with tilavonemab.

Published on Oct 1, 2021in Lancet Neurology44.182
· DOI :10.1016/S1474-4422(21)00283-0
Shunsuke Koga23
Estimated H-index: 23
(Mayo Clinic),
Dennis W. Dickson218
Estimated H-index: 218
(Mayo Clinic),
Zbigniew K. Wszolek105
Estimated H-index: 105
(Mayo Clinic)
#1Boram Kim (UPenn: University of Pennsylvania)H-Index: 3
#2Bailey Mikytuck (UPenn: University of Pennsylvania)H-Index: 1
Last. Edward B. Lee (UPenn: University of Pennsylvania)H-Index: 60
view all 12 authors...
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologic subtypes of frontotemporal lobar degeneration with tau inclusions (FTLD-tau), primary tauopathies in which intracellular tau aggregation contributes to neurodegeneration. Gosuranemab (BIIB092) is a humanized monoclonal antibody that binds to N-terminal tau. While Gosuranemab passive immunotherapy trials for PSP failed to demonstrate clinical benefit, Gosuranemab reduced N-terminal tau in the cerebrospina...
#1Günter U. Höglinger (MHH: Hannover Medical School)H-Index: 59
#2Irene Litvan (UCSD: University of California, San Diego)H-Index: 101
Last. Kumar Budur (AbbVie)H-Index: 7
view all 72 authors...
Summary Background Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy. Methods We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and...
#1Steven S. Plotkin (UBC: University of British Columbia)H-Index: 22
#2Neil R. Cashman (UBC: University of British Columbia)H-Index: 63
Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat Alzheimer's disease. The most extensively developed method to treat the pathologic forms of these proteins is through the administration of exogenous antibodies, or passive immunotherapy. In this review, we discuss the molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating this disease. These challenges include selectively target...
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome. Objective: We aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for PSP. Methods: We searched the PubMed, Cochrane, Medlin...
#1Tim WestH-Index: 11
#2Yan HuH-Index: 12
Last. David M. HoltzmanH-Index: 183
view all 10 authors...
: Tau neurofibrillary tangles are found in the brains of patients suffering from Alzheimer's disease and other tauopathies. The progressive spreading of tau pathology from one brain region to the next is believed to be caused by extracellular transsynaptic transmission of misfolded tau between neurons. Preclinical studies have shown that antibodies against tau can prevent this transfer of misfolded tau between cells. Thus, antibodies against tau have the potential to stop or slow the progression...
#1Kiran Yanamandra (WashU: Washington University in St. Louis)H-Index: 12
#2Najla Kfoury (WashU: Washington University in St. Louis)H-Index: 7
Last. David M. Holtzman (WashU: Washington University in St. Louis)H-Index: 183
view all 9 authors...
Summary Tau aggregation occurs in neurodegenerative diseases including Alzheimer's disease and many other disorders collectively termed tauopathies. trans -cellular propagation of tau pathology, mediated by extracellular tau aggregates, may underlie pathogenesis of these conditions. P301S tau transgenic mice express mutant human tau protein and develop progressive tau pathology. Using a cell-based biosensor assay, we screened anti-tau monoclonal antibodies for their ability to block seeding acti...
Cited By1
#1Günter U. Höglinger (German Center for Neurodegenerative Diseases)H-Index: 59
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.